Atara Biotherapeutics, Inc.
ATRA
$9.91
-$0.32-3.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -96.42% | -99.47% | -95.13% | -91.41% | -38.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -96.42% | -99.47% | -95.13% | -91.41% | -38.63% |
| Cost of Revenue | -77.80% | -99.27% | -96.45% | -94.13% | -81.60% |
| Gross Profit | -108.50% | -99.61% | -92.41% | 103.78% | 218.88% |
| SG&A Expenses | -48.66% | -64.07% | -63.26% | -61.86% | -33.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -64.35% | -92.16% | -84.18% | -88.70% | -72.36% |
| Operating Income | -183.75% | -106.93% | 54.79% | 83.70% | 126.41% |
| Income Before Tax | -302.22% | -110.91% | 73.21% | 80.50% | 112.55% |
| Income Tax Expenses | -66.67% | -- | 100.00% | 264.71% | -- |
| Earnings from Continuing Operations | -302.51% | -110.91% | 73.17% | 80.36% | 112.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -302.51% | -110.91% | 73.17% | 80.36% | 112.53% |
| EBIT | -183.75% | -106.93% | 54.79% | 83.70% | 126.41% |
| EBITDA | -179.48% | -106.63% | 59.76% | 84.08% | 129.11% |
| EPS Basic | -264.33% | -108.34% | 78.90% | 89.19% | 106.31% |
| Normalized Basic EPS | -184.29% | -106.63% | 60.66% | 89.34% | 110.54% |
| EPS Diluted | -269.26% | -108.41% | 78.91% | 89.10% | 106.13% |
| Normalized Diluted EPS | -185.05% | -106.68% | 60.66% | 89.34% | 110.45% |
| Average Basic Shares Outstanding | 23.25% | 30.82% | 27.18% | 81.68% | 98.55% |
| Average Diluted Shares Outstanding | 22.12% | 29.77% | 27.18% | 81.68% | 100.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |